Therapeutic Goods Administration

Therapeutic Goods Administration
Name	Therapeutic Goods Administration
Formed	1990
Jurisdiction	Australian Government
Headquarters	Symonston, Australian Capital Territory
Minister1 name	Mark Butler
Minister1 pfo	Minister for Health and Aged Care
Chief1 name	Adjunct Professor John Skerritt
Chief1 position	Deputy Secretary, Health Products Regulation Group
Parent department	Department of Health and Aged Care
Website	https://www.tga.gov.au

Therapeutic Goods Administration. It is the regulatory body responsible for ensuring the safety, quality, and efficacy of therapeutic goods available in Australia. Operating within the Department of Health and Aged Care, its oversight encompasses medicines, medical devices, biologicals, and blood products. The agency's work is critical to public health, balancing timely access to new therapies with robust safety monitoring.

History

The origins of national therapeutic goods regulation in Australia trace back to the early 20th century, with individual states managing controls under various pharmacy acts. A pivotal shift occurred with the passage of the Therapeutic Goods Act 1989 by the Parliament of Australia, which established a cohesive national framework. Commencing operations in 1990, it replaced the previous fragmented system, creating a centralized authority. Key milestones include the incorporation of medical device regulation in 2002 and the agency's pivotal role during public health emergencies like the COVID-19 pandemic in Australia.

Functions and responsibilities

Its core mandate is to administer the Therapeutic Goods Act 1989 and associated legislation, safeguarding public health. This involves pre-market assessment and approval for all therapeutic goods before they can be supplied in Australia, except for certain exempt items. Post-market, it conducts surveillance, monitors adverse events through systems like the Database of Adverse Event Notifications, and ensures compliance through enforcement actions. The agency also maintains the Australian Register of Therapeutic Goods, the official record of approved products, and provides scientific advice to the Minister.

Regulatory framework

The principal legislation is the Therapeutic Goods Act 1989, which sets out the requirements for import, export, manufacture, and supply. Supporting regulations include the Therapeutic Goods Regulations 1990 and specific orders for medical devices and blood. This framework classifies medicines into categories like prescription, over-the-counter, and complementary, and devices into classes based on risk. The agency's decisions are also informed by guidelines from international bodies such as the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.

Key regulatory processes

For medicines, the process involves a detailed evaluation of data on quality, safety, and efficacy, often referencing assessments from agencies like the European Medicines Agency or the United States Food and Drug Administration. Medical devices are assessed under conformity assessment procedures, which may require audit of manufacturing practices. All approved products are listed on the Australian Register of Therapeutic Goods. The agency also manages special access schemes for unapproved goods and runs the Pharmacovigilance program to monitor safety after products enter the market.

International cooperation

The agency actively engages in global harmonization efforts to align standards and facilitate trade. It is a founding member of the Asia-Pacific Economic Cooperation Life Sciences Innovation Forum Regulatory Harmonization Steering Committee. It has mutual recognition agreements with counterparts like the Therapeutic Products Directorate of Health Canada and participates in the Pharmaceutical Inspection Co-operation Scheme. These collaborations allow for work-sharing on evaluations and inspections, enhancing regulatory efficiency and capacity, particularly within the Asia-Pacific region.

Criticisms and controversies

The agency has faced scrutiny over the pace of approvals, with some patient groups and industry stakeholders arguing for faster access to new therapies, akin to the Food and Drug Administration's accelerated pathways. Its handling of complementary medicines has been questioned by reviews like the 2011 Australian National Audit Office report. During the COVID-19 pandemic, its approval processes for COVID-19 vaccines and treatments, such as those from Pfizer and Moderna, were intensely watched and sometimes debated publicly. Decisions regarding specific products, including the painkiller Diclofenac sodium, have also attracted controversy from time to time.

Category:Australian Government agencies Category:Health in Australia Category:1990 establishments in Australia